Callan JMB Inc. (CJMB) surged sharply on Thursday, rising 240.05 percent, or $2.7107, after the company announced a strategic teaming agreement with Attune Biotech Inc., a clinical-stage biopharmaceutical company.
The stock was trading at $3.8307 after opening at $1.12, unchanged from its previous close of $1.12. Shares traded in a wide range between $2.54 and $5.61 during the session.
Trading volume spiked to approximately 171.86 million shares, far above the average volume of 39,161, reflecting heavy investor interest following the announcement.
Under the agreement, Callan JMB will act as an independent third-party overseer of Attune's manufacturing, quality assurance, and deployment operations, providing federal oversight services including BARDA compliance, FDA audit readiness, supply chain governance, and Strategic National Stockpile deployment coordination. Callan JMB's 52-week range stands at $1.0820 to $7.7600.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.